Welcome to our dedicated page for Primerica SEC filings (Ticker: PRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Primerica's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Primerica's regulatory disclosures and financial reporting.
Primerica director Joel M. Babbit reported a non-derivative acquisition on 09/15/2025 that added 28.6055 shares of phantom stock through automatic reinvestment of dividends under the Non-Employee Directors' Deferred Compensation Plan. Phantom stock converts one-for-one into common stock. The filing shows a reported price of $274.23 per share and indicates Mr. Babbit now beneficially owns 9,100.3759 shares (direct). The transaction was reported on Form 4 and signed on 09/16/2025 by an attorney-in-fact.
Insider sale by Primerica President Peter W. Schneider. The Form 4 shows Mr. Schneider executed a sale of 2,000 shares of Primerica, Inc. (PRI) on 08/18/2025 at an average price of $261.1649, with reported trade prices ranging from $259.64 to $262.48. After the sale he beneficially owned 9,301 shares, reported as direct ownership.
The filing indicates the transaction was made pursuant to a 10b5-1 trading plan (box checked). The Form 4 was signed by an attorney-in-fact, Stacey K. Geer, on 08/19/2025. No derivative transactions or other securities classes are reported.
Form 144 filed for Primerica, Inc. (PRI) reports a proposed sale of 4,000 shares of common stock through Morgan Stanley Smith Barney on 08/18/2025 with an aggregate market value of $1,046,680.00. The shares were originally acquired as restricted stock awards on 02/21/2015. The filer previously sold 2,000 shares on 05/19/2025 under a 10b5-1 plan, generating gross proceeds of $560,739.40. The filing lists 32,391,333 shares outstanding for the issuer and states the sale will occur on the NYSE.
Primerica reported a Form 4 showing that Glenn J. Williams, who is listed as both a director and the Chief Executive Officer, disposed of shares on 08/12/2025. The filing records a sale of 2,500 shares of Common Stock at a weighted average price of $262.2035. After the reported sale, Mr. Williams is shown as beneficially owning 36,391.995 shares directly. The transaction is coded as a sale and the form was executed on 08/12/2025 by Stacey K. Geer as attorney in fact. The filer explains the weighted average reflects multiple trade prices ranging from $259.22 to $264.34.
Primerica, Inc. (PRI) filed a Form 144 notifying a proposed sale of 2,500 shares of common stock through Morgan Stanley Smith Barney on the NYSE with an indicated aggregate market value of $645,675.00. The shares were acquired as Restricted Stock Units on 03/01/2025 and the filing lists an approximate sale date of 08/12/2025. The filing also discloses a prior 10b5-1 sale of 2,500 shares on 06/13/2025 generating gross proceeds of $647,591.25. Outstanding shares are shown as 32,391,333, making the proposed block a very small percentage of the company.
Primerica Q2 2025 10-Q highlights
- Revenue inched up 0.3% YoY to $793.3 million; commissions & fees rose 14% while net premiums grew 3.6%.
- Pre-tax income from continuing ops fell 14% to $234.5 million; net income declined to $178.3 million (-15%) as prior-year results contained a one-off $50 million insurance recovery.
- Diluted EPS from continuing ops dropped to $5.40 (-11%); total diluted EPS unchanged by discontinued Senior Health unit, which caused a $208 million loss in Q2 2024.
- Segment performance: Term Life pre-tax profit +5% to $155.0 million; Investment & Savings Products +6% to $79.4 million; Corporate & Other near breakeven versus $50.2 million profit last year.
- Capital returns: 2Q buybacks of $127 million and dividends of $34 million reduced diluted share count 4% YoY to 32.9 million; YTD repurchases total $251 million.
- Balance sheet: Assets $14.83 b (+2% YTD); equity $2.31 b (+2%). Cash fell to $621 million after $329 million financing outflows. AOCI improved by $63 million YTD on discount-rate and FX movements.
- Liquidity & cash flow: Operating cash flow solid at $360 million versus $384 million YTD 2024; investing cash outflow $100 million driven by portfolio reinvestment.
Bottom line: Core franchises showed modest growth, but elevated expenses and loss of 2024’s non-recurring gain compressed margins. Shareholder payouts remain aggressive, sustaining mid-teens ROE.